Wang G, Wu Y, Zhou T, Guo Y, Zheng B, Wang J et al
Like most chronic therapies, GLP-1s are most effective when used consistently, so a formulation that encourages long-term use could have a meaningful impact on patient outcomes.
GLP-1 receptor agonists are licensed to treat diabetes and obesity, but data on whether these medications alleviate or exacerbate anxiety, depression, and self-harm are mixed
Firoze Khan [email protected] This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers